3 Specialty Branded Generics, Global Generics and Injectables and Cardiac Therapy Leader Stocks With a Strong Future Roadmap: Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals
- October 23, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals: ROE of 9.2% to 25.5% and FY22 to FY26 revenue CAGR of 9.5% to 12.9%. Prices as of 22 Oct 2026.
Quick Answer
The three branded generic and global formulation stocks to watch are Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals. Their return on equity ranges from 9.2% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 12.9%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Ajanta Pharma has the fastest revenue growth at 12.9% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Branded generic and global formulation stocks let investors follow pharmaceutical companies that sell finished medicines in many markets. Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals cover specialty branded generics, global generics and injectables, and a leader in cardiac and central nervous system therapies.
This list covers three branded generic and global formulation stocks with complete current figures: Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generic and Global Formulation Stocks?
Branded generic and global formulation stocks are listed pharmaceutical companies that sell prescription brands and generic medicines in India and overseas. Their earnings depend on launches, market share and plant compliance.
Branded Generic and Global Formulation Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ajanta Pharma | 3,270.6 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Aurobindo Pharma | 1,610.9 | 92,924 | 25.0 | 36.0 | 9.2 | 0.21 |
| Torrent Pharmaceuticals | 4,615.3 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
On valuation, Aurobindo Pharma trades at a P/E below the industry P/E, while Ajanta Pharma and Torrent Pharmaceuticals trade above it, which reflects the growth the market already expects. Readers comparing branded generic and global formulation stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded generic and global formulation stocks can use the coming numbers to test whether growth is holding.
Why Do Branded Generic and Global Formulation Stocks Have a Strong Roadmap in India?
Branded generic and global formulation stocks have a strong roadmap in India because the domestic market is growing steadily and global buyers keep turning to Indian makers for affordable, quality medicines.
- Branded strength. Doctor-trusted brands hold share in chronic therapies.
- Global reach. Sales across regulated and emerging markets spread earnings.
- Injectables and complex products. Harder-to-make products earn better margins.
Why Ajanta Pharma Features Among These Branded Generic and Global Formulation Stocks
Among the branded generic and global formulation stocks on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.
Why Aurobindo Pharma Features Among These Branded Generic and Global Formulation Stocks
Among the global pharma formulation shares on this list, Aurobindo Pharma is a Hyderabad-based pharmaceutical company that makes generic formulations, active ingredients and injectables, with the United States and Europe as its largest markets.
Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%.
In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0.
Roadmap: The company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.
What to watch: Monitor new product launches and progress on its biosimilars and injectables pipeline.
Why Torrent Pharmaceuticals Features Among These Branded Generic and Global Formulation Stocks
Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%.
Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Ajanta Pharma vs Aurobindo Pharma vs Torrent Pharmaceuticals on Key Financials
The table below sets the three branded generic and global formulation stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Aurobindo Pharma | 23,776 | 34,145 | 9.5% | 3,503 | 10.3% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Aurobindo Pharma has the largest FY26 revenue at Rs 34,145 crore, and Ajanta Pharma shows the fastest revenue growth with a 12.9% compound annual rate. A useful habit with branded generic and global formulation stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several export pharma growth stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Ajanta Pharma | 1,329 | 1,697 | 27.7% |
| Aurobindo Pharma | 7,973 | 9,415 | 18.1% |
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
Key Risks to Check Before Investing in Branded Generic and Global Formulation Stocks
Every theme carries risks that deserve a check before any decision. For these branded generic and global formulation stocks, the main points are: Long-term global pharma formulation shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Price controls. Government limits on listed medicines can cap realisations.
- Plant inspections. Regulatory reviews of manufacturing sites can delay supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generic and global formulation stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generic and Global Formulation Stocks
Branded generic and global formulation stocks reward investors who follow launches, market share and plant compliance together. Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals each have room to widen their reach. Based on the 22 October 2026 close, Ajanta Pharma trades at Rs 3,270.6, Aurobindo Pharma at Rs 1,610.9 and Torrent Pharmaceuticals at Rs 4,615.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generic and global formulation stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generic and global formulation stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generic and global formulation stocks?
Ans. Branded generic and global formulation stocks are listed pharmaceutical companies that sell prescription brands and generic medicines in India and overseas. Their earnings depend on launches, market share and plant compliance. This list looks at three of them, Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which branded generic and global formulation stocks are covered in this list?
Ans. This list covers Ajanta Pharma, Aurobindo Pharma and Torrent Pharmaceuticals. Based on the 22 October 2026 close, Ajanta Pharma traded at Rs 3,270.6, Aurobindo Pharma at Rs 1,610.9 and Torrent Pharmaceuticals at Rs 4,615.3. Their return on equity ranges from 9.2% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 12.9%.
Why do branded generic and global formulation stocks have a strong future roadmap in India?
Ans. Branded generic and global formulation stocks have a strong roadmap in India because the domestic market is growing steadily and global buyers keep turning to Indian makers for affordable, quality medicines. The main drivers are as follows. Branded strength. Doctor-trusted brands hold share in chronic therapies. Global reach. Sales across regulated and emerging markets spread earnings. Injectables and complex products. Harder-to-make products earn better margins. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Aurobindo Pharma performed financially?
Ans. Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0. Looking ahead, the company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What risks should investors check before buying branded generic and global formulation stocks?
Ans. Investors should check a few risks before buying branded generic and global formulation stocks. Price controls. Government limits on listed medicines can cap realisations. Plant inspections. Regulatory reviews of manufacturing sites can delay supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generic and global formulation stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
